CAR-TCR Conversion with
Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company
In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.
CAR-TCR Conversation with David Sourdive Executive Vice President, Technical Operations & Co-founder
In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies
CAR-TCR Industry Survey 2018
The infographic provides some great insights into solid tumor approaches, commercial impact and limitations of manufacturing strategies.
Interviews with: Juno Therapeutics, Cellectis, ZIOPHARM, Kite Pharma
On a mission to find out what the future holds for the CAR-TCR space, we sat down with: Hans Bishop, CEO, Juno Therapeutics; André Choulika, CEO, Cellectis; Laurence Cooper, CEO, ZIOPHARM and David Chang, CMO, Kite, Pharma to talk shop.
CAR-TCR Industry Survey 2017
The industry results provide some great insights into manufacturing challenges, key design factors for the next generation of CAR-TCR therapies and pricing models for these therapies.
Major Highlights of the CAR-TCR Summit, Boston 2016
Vita Golubovskaya, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu present their highlights from the CAR-TCR Summit 2016